Jourdan M - Search Results

1

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, Moehler T, Rossi JF, Rème T, Goldschmidt H, Klein B. Mahtouk K, et al. Among authors: jourdan m, jourdan e. Blood. 2007 Jun 1;109(11):4914-23. doi: 10.1182/blood-2006-08-043232. Epub 2007 Mar 5. Blood. 2007. PMID: 17339423 Free PMC article.

2

Mutations of the p53 gene in human myeloma cell lines.

Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C, Klein B. Mazars GR, et al. Among authors: jourdan m. Oncogene. 1992 May;7(5):1015-8. Oncogene. 1992. PMID: 1373872

3

Up-regulation of interleukin (IL)-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells.

Portier M, Lees D, Caron E, Jourdan M, Boiron JM, Bataille R, Klein B. Portier M, et al. Among authors: jourdan m. FEBS Lett. 1992 May 4;302(1):35-8. doi: 10.1016/0014-5793(92)80278-o. FEBS Lett. 1992. PMID: 1587349 Free article.

4

Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease.

Klein B, Zhang XG, Jourdan M, Portier M, Bataille R. Klein B, et al. Among authors: jourdan m. Curr Top Microbiol Immunol. 1990;166:23-31. doi: 10.1007/978-3-642-75889-8_3. Curr Top Microbiol Immunol. 1990. PMID: 1705876 Review. No abstract available.

5

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, et al. Klein B, et al. Among authors: jourdan m. Blood. 1991 Sep 1;78(5):1198-204. Blood. 1991. PMID: 1715218 Free article.

6

IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.

Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B. Jourdan M, et al. J Immunol. 1991 Dec 15;147(12):4402-7. J Immunol. 1991. PMID: 1753108

7

Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.

Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R. Klein B, et al. Among authors: jourdan m. Eur Cytokine Netw. 1990 Oct-Nov;1(4):193-201. Eur Cytokine Netw. 1990. PMID: 2104241 Review.

8

Human natural killer cells suppress the proliferation of B cells.

Commes T, Clofent G, Jourdan M, Bataille R, Klein B. Commes T, et al. Among authors: jourdan m. Immunol Lett. 1990 Mar-Apr;24(1):57-61. doi: 10.1016/0165-2478(90)90036-p. Immunol Lett. 1990. PMID: 2142675

9

Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells.

Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B. Zhang XG, et al. Among authors: jourdan m. Blood. 1990 Dec 15;76(12):2599-605. Blood. 1990. PMID: 2265252 Free article. Clinical Trial.

10

The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors.

Commes T, Klein B, Jourdan M, Clofent G, Houssiau F, Grenier J, Bataille R. Commes T, et al. Among authors: jourdan m. J Clin Immunol. 1989 Jan;9(1):65-73. doi: 10.1007/BF00917129. J Clin Immunol. 1989. PMID: 2495299

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

310 results

Search Page